Home Systems biology Berkeley Lights Announces GSK Acquires Third Beacon® Optofluidic System to Develop Antibodies...

Berkeley Lights Announces GSK Acquires Third Beacon® Optofluidic System to Develop Antibodies … | Your money

6
0

EMERYVILLE, Calif., October 26, 2021 (GLOBE NEWSWIRE) – Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced that GlaxoSmithKline (NYSE: GSK) has purchased an optofluidic Beacon â„¢ additional system to expand its therapeutic capacity based on antibodies. The new Beacon system will take advantage of Berkeley Lights’ Opto â„¢ Plasma B Discovery workflow to perform functional analysis, further speeding up the prospect selection process.

“We are delighted that GSK has once again selected the Beacon Optofluidic System as part of its ongoing activities to accelerate the discovery, development and delivery of therapeutics,” said Eric Hobbs, Ph.D., CEO of Berkeley Lights. “BLI’s platform represents a radical change in high throughput screening technology and can be used to discover new perspectives in functional biology research and therapeutic discovery. The growing adoption of GSK demonstrates the value of our streamlined functional screening platform that is capable of observing rare interactions, underpinned by a unique combination of high throughput screening and living biology.

The Beacon System purchased by GSK includes the 13 new platform locations for the quarter ended September 30, 2021, which was pre-announced on October 12, 2021.

Learn more about the Beacon System The Beacon System is the most flexible and advanced functional high-throughput screening platform on the market, with customers using the technology as their competitive advantage in a variety of markets, including antibody discovery and cell line development, gene therapy and synthetic biology.

Beacon System Workflow has proven to be a better and more advanced way to process and analyze cells which saves customers time, money and effort due to its:

Single cell based workflow that shortens the selection process to just days; Monitoring of the phenotype and genotype of individual cells or clones; Automation and scaling of workflows far beyond tedious manual analysis; and Generating better information through in-depth profiling of each cell or clone.

Berkeley Lights Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights platform captures in-depth phenotypic, functional and genotypic information for thousands of individual cells in parallel and can also deliver the living biology customers want in the form of the best cells. Our platform is a fully integrated, end-to-end solution, including proprietary consumables including our OptoSelect â„¢ reagent chips and kits, advanced automation systems and application software. We have developed the Berkeley Lights platform to provide the most advanced environment for rapid functional characterization of large-scale single cells, the goal of which is to set an industry standard for our customers throughout their production chain. value of cellular products.

The Berkeley Lights Beacon® and Lightning ™ systems and the Culture Station ™ instrument are FOR RESEARCH ONLY. Not for use in diagnostic procedures.

Forward-looking statements To the extent that the statements contained in this press release are not descriptions of historical facts about Berkeley Lights or its products, they are forward-looking statements reflecting the current views and expectations of management. These forward-looking statements involve substantial known and unknown risks and uncertainties relating to future events, and actual results and product performance could differ materially from those expressed or implied by the forward-looking statements. Berkeley Lights assumes no obligation to update or revise any forward-looking statements. For a more detailed description of the risks and uncertainties associated with the growth and continued development of the Company, see the statements in the “Risk Factors” sections and elsewhere, in our filings with the State Securities and Exchange Commission. -United.

Media contacts Media@berkeleylights.com

Investor contact IR@berkeleylights.com

Copyright 2021 GlobeNewswire, Inc.


Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here